CollaGenex Pharmaceuticals to Present at the UBS Warburg Global Specialty Pharmaceuticals Conference on June 6, 2002.Business Editors/Health & Medical Writers UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Warburg Global Specialty Pharmaceuticals Conference NEWTOWN, Pa.--(BUSINESS WIRE)--May 30, 2002 CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI CGPI Corporate Goods Price Index (Japan) CGPI Capital Goods Price Index (New Zealand) ) announced today that the Company's chairman, president and chief executive officer, Brian M. Gallagher, PhD, will present at the UBS Warburg Global Specialty Pharmaceuticals Conference. The presentation is scheduled for 9:30 AM on June 6, 2002 at the Grand Hyatt Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . The presentation will be available as a live audio webcast at http://webcast.mediaondemand.com/ubs/20020605. A replay will be available 24 hours after the actual presentation time until July 6, 2002. CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company currently focused on providing innovative medical therapies to the dental and dermatology markets. Currently, the Company's 120-person professional dental pharmaceutical sales force markets Periostat(R), the first and only pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy periodontal support tissues, Vioxx(R), a Merck & Co. drug that CollaGenex co-promotes for the treatment of acute dental pain, and Atridox(R), Atrisorb(R) and Atrisorb-D(R), Atrix Laboratories Inc.'s products for the treatment of adult periodontitis periodontitis Inflammation of soft tissues around the teeth (see tooth). Poor dental hygiene leads to deposition of bacterial plaque on the teeth below the gum line, irritating and eroding nearby tissues. . Research has shown that the enzyme suppression technology underlying Periostat may also be applicable to other diseases involving inflammation and/or destruction of the body's connective tissues, including acne, rosacea Rosacea Definition Rosacea is a skin disease typically appearing in people during their 30s and 40s. It is marked by redness (erythema) of the face, flushing of the skin, and the presence of hard pimples (papules) or pus-filled pimples (pustules), and , blepharitis blepharitis /bleph·a·ri·tis/ (blef?ah-ri´tis) inflammation of the eyelids. blepharitis angula´ris inflammation involving the angles of the eyelids. and cancer metastases, among others. CollaGenex is further developing Periostat as well as a series of novel, proprietary compounds known as IMPACS IMPACS Institute for Media, Policy and Civil Society IMPACS Integrated Manufacturing Planning and Control System IMPACS International Message and Packet Switching Service (Inhibitors of Multiple Proteases and Cytokines) to address these applications. To receive additional information on the Company, please visit our Web site at www.collagenex.com. Periostat(R), Metastat(R) and IMPACS(R) are trademarks of CollaGenex Pharmaceuticals, Inc. VIOXX(R)is a trademark of Merck & Co., Inc. Atridox, Atrisorb and Atrisorb-D are trademarks of Atrix Laboratories, Inc. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion